The National Heart, Lung, and Blood Institute (NHLBI) awarded a $356,250 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Vasarya Therapeutics, Inc., a woman-owned small business, to develop a novel drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF). The goal of this Fast-Track SBIR project is to perform affinity maturation and liability assessment to create a pool of candidate antibody drugs, then select a primary drug candidate and establish its translatability through pharmacokinetic, toxicity, safety, and efficacy analyses in animal models. The funded work aims to position the company to initiate IND-enabling studies for this potential IPF treatment upon successful completion of the project by September 2025.
Generated 1/28/25, 9:37 AM